加载中…
Anti-CD30 Antibody (Brentuximab Biosimilar) is a research-use biosimilar antibody expressed in HEK293. The source page specifies target CD30, reactivity Human/Cynomolgus, isotype Human IgG1-Kappa, source-listed application ELISA.
The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin's lymphomas (NHLs).
